You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

EDECRIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Edecrin, and what generic alternatives are available?

Edecrin is a drug marketed by Bausch and is included in two NDAs.

The generic ingredient in EDECRIN is ethacrynic acid. There are thirteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the ethacrynic acid profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Edecrin

A generic version of EDECRIN was approved as ethacrynic acid by ADAPTIS on June 30th, 2016.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for EDECRIN?
  • What are the global sales for EDECRIN?
  • What is Average Wholesale Price for EDECRIN?
Summary for EDECRIN
Drug patent expirations by year for EDECRIN
Drug Prices for EDECRIN

See drug prices for EDECRIN

Recent Clinical Trials for EDECRIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eugene Lee, MDPhase 1
University of Kansas Medical CenterPhase 1

See all EDECRIN clinical trials

Pharmacology for EDECRIN
Drug ClassLoop Diuretic
Physiological EffectIncreased Diuresis at Loop of Henle

US Patents and Regulatory Information for EDECRIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch EDECRIN ethacrynate sodium INJECTABLE;INJECTION 016093-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bausch EDECRIN ethacrynic acid TABLET;ORAL 016092-001 Approved Prior to Jan 1, 1982 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bausch EDECRIN ethacrynic acid TABLET;ORAL 016092-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.